Oklahoma Medical Research Foundation scientist Benjamin Miller, Ph.D., leads a team of researchers working to improve medical and treatment practices by developing a better understanding of the biological process of aging.
Why study aging?
As we grow older, we are more likely to develop Type 2 diabetes, cardiovascular disease, Alzheimer’s and many other conditions that are difficult and expensive to treat. Scientists believe that slowing aging may delay or prevent chronic diseases rather than treating these diseases one at a time.
We want to extend the number of healthy years in people’s lives. You can help.
Join our study
With the help of healthy individuals who are 40-75 years old, Dr. Miller’s team studies whether Metformin, an FDA-approved drug currently used to treat Type 2 diabetes, can help slow aging and delay the onset of chronic diseases.
If you decide to join us in this project, your participation will include a phone screening to determine your eligibility.
Once enrolled, you’ll undergo a medical screening and a scan to determine your body composition at the OU Health Harold Hamm Diabetes Center in Oklahoma City. In a separate visit, you will have a small muscle biopsy and undergo a test to determine how well you process sugar. You will then be given Metformin or placebo to be taken over 12 weeks before repeating the previous onsite procedures. You’ll be compensated for effort related to the study.
Who can participate?
You may qualify if you are:
- Male or female between the ages of 40-75 years old
- Have a higher than normal blood sugar (100-125 mg/dL), HbA1c (5.7-6.4%) or if your doctor has told you that you are at risk of developing Type 2 diabetes. If you do not know, we can check these values at no cost to you.
- Have a BMI >30 kg/m2 or if you are not physically active
- Not currently taking glucose-lowering agents
Start the enrollment process today:
Oklahoma Shared Clinical and Translational Resources
Meet the Miller Lab
Learn more about Dr. Miller’s research >>
The University of Oklahoma is an equal opportunity institution. IRB #10699. IRB approval date: 06/18/2022.